

20th IELSG ANNUAL MEETING

MARCH 17-18, 2017

ARCOTEL Camino | Heilbronner Straße 21 | 70191 Stuttgart (Germany)



Schlossplatz Stuttgart

08:00 – 10:00 **CLOSED MEETING**
Meeting of the Latin American Investigators:
“Can we launch collaborative retrospective studies on extranodal lymphoma in Latin America?”

13:00 - 13:30 Registration On-Site

13:30 Welcome and Introductory Remarks
E. Zucca

13:45 – 15:30 IELSG STUDY DISCUSSIONS 1

Chair: M. Gospodarowicz

CNS LYMPHOMA

13:45 Report on the EPCG Meeting + Upcoming “FIORELLA” Trial and Latest News on IELSG32
A. Ferreri

14:15 IELSG43 “MATRIX”, the Randomized Study on Primary CNS Lymphoma
G. Illerhaus

14:30 Follow-On Trials on Primary CNS
A. Ferreri

15:00 IELSG42 “MARIETTA”, the Study on Systemic DLBCL with Secondary CNS Involvement
A. Ferreri

TESTIS LYMPHOMA

15:15 IELSG30: Study Update
A. Chiappella

15:30 - 16:00 Coffee Break

16:00 - 16:30 IELSG STUDY DISCUSSIONS 2

Chair: J. Seymour

PRIMARY MEDIASTINAL LYMPHOMA

16:00 IELSG37: Study Update
A. Davies and M. Martelli

16:15 IELSG26 study of Primary Mediastinal B-Cell Lymphoma: Identification of 18-FDG PET-associated Biomarkers
L. Ceriani and E. Zucca

16:30 - 17:15 PROPOSALS FOR NEW STUDIES

16:30 New Study on Primary Mediastinal B-Cell Lymphoma
G. Nowakowski and A. Dąbrowska-Iwanicka

16:45 Retrospective Study on T-Cell Neoplasms in Collaboration with Latin America
S. Luminari

17:00 IELSG44: A phase II study of subcutaneous rituximab in combination with venetoclax in patients with previously treated marginal zone lymphoma (MZL)
A. Stathis

17:15 - 18:00 EDUCATIONAL LECTURE

The 2016 Update of the WHO Classification of Lymphoid Tissue Tumours
L. Quintanilla-Fend

18:30 Mercedes-Benz-Museum Guided Tour

20:00 Dinner at the Mercedes-Benz-Museum

09:00 – 10:00 IELSG STUDY DISCUSSIONS 2

Chair: F. Cavalli

MARGINAL ZONE LYMPHOMA 1

09:00 IELSG46: Biologic Retrospective Study in SMZL

D. Rossi and L. Arcaini

09:20 “MALIBU”: The Next IELSG Randomized Trial on MZL

C. Thieblemont

10:00 – 10:45 IELSG STUDY DISCUSSIONS 3

Chair: E. Zucca

MARGINAL ZONE LYMPHOMA 2

10:00 IELSG38: Study Update - Results of the First Analysis

A. Stathis

10:15 IELSG39 On Ocular Adnexa Lymphoma

A. Ferreri and M. Ponzoni

10:30 IELSG40 “CLEO” (Lenalidomide + Clarithromycin): Study Update

A. Ferreri

10:45 - 11:00 Coffee break

11:00 - 12:00 GENERAL ASSEMBLY

Chair: F. Cavalli

Discussion of Administrative Issues, Report of the Board of Directors’ Meeting and Closing Remarks

We thank for the kind educational unrestricted support:



The working dinner-meeting is kindly supported by:

AbbVie Deutschland GmbH & Co. KG (10.000€)
Bristol-Myers Squibb GmbH & Co. KGaA (3.000€)
Celgene GmbH (1.500€)

Janssen-Cilag GmbH (1.500€)
Roche Pharma AG (3.000€)
Takeda Pharma Vertrieb GmbH & Co. KG (1.500€)



INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
STUDY COORDINATION

Oncology Institute of Southern Switzerland, Ospedale Regionale di Bellinzona e Valli, CH-6500 Bellinzona (Switzerland)
Phone +41 91 811 90 40 Fax +41 91 811 91 82 E-mail ielsg@eoc.ch www.ielsg.org